In this episode, host Shikha Jain, MD, speaks with Opyl co-founder Damon Rasheed about using machine learning to better predict clinical trial outcomes, handling ethical concerns surrounding AI in health care and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Rasheed 0:20 •    The interview 0:58 •    How did you end up in the AI-powered medicine and clinical trials?  1:48 •    What is Opyl, and what is TrialKey? 3:54 •    Is TrialKey predominantly based in Australia or is it available outside of Australia as well? 5:34 •    Can you explain how machine learning works in order to create these outcomes?  6:11 •    How do you see people utilizing this tool in the future based on what you have already seen?  8:30 •    How have others received this? What is the feedback you have gotten surrounding what people are excited and concerned about with this technology?  10:50 •    Does this type of product take into account the issue of diversity in clinical trials?  13:41 •    What’s next for expanding Opyl and TrialKey?  14:27 •    What keeps you excited and motivated to continue working in this space?  15:28 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 19:35 •    How to contact Rasheed 20:16 •    Thanks for listening 20:54 Damon Rasheed is a serial entrepreneur recognized for his groundbreaking ventures and deep expertise in machine learning and big data.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rasheed can be reached at opyl.ai or trialkey.ai. 

Disclosures: Jain reports no relevant financial disclosures. Rasheed reports TrialKey is powered by Opyl Limited, which is a publicly listed company operating on the ASX.

In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the ASH Annual Meeting and Exhibition, as well as Healio’s top headlines from the meeting.

Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients’ concerns as AI’s role in medicine invariably expands. :24

Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29

Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30

Read the full coverage here:

AI in hematology: ‘The good, the bad and the ugly’

Mitigating financial toxicity ’better than any drug’ for people with cancer

Etavopivat could offer ‘great benefit’ in sickle cell disease

ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award

GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no financial disclosures. Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Gandara 0:19 •    The interview 1:02 •    Can you tell me a little more about what you are working on now? 1:25 •    How did you get engaged with the community in Hawaii?  6:30 •    What do you think is going to happen with ctDNA moving forward? 8:29 •    Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy?  11:42 •    How did you get into the ctDNA space?  15:06 •    How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health?  18:28 •    Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do?  23:17 •    What are some of your predictions as to what will happen in oncology care over the next ten to twenty years?  29:00 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30 •    How to contact Gandara 38:47 •    Thanks for listening 39:10 David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email [email protected]. 

Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine. 

In this episode, host Shikha Jain, MD, speaks with Michel van Harten, MD, about creating better information systems for physicians and patients, how shared decision-making can improve drug development and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About van Harten 0:20 •    The interview 1:00 •    What was your journey to becoming a physician and beyond to where you are now? 1:24 •    How did you learn the necessary skills to be an exceptional leader in this space?  2:51 •    How many years were you a practicing physician for? 3:53 •    What does myTomorrows do, and what drew you to this type of work? 4:54 •    Where is this service available?  7:19 •    Jain and van Harten on the challenges patients face surrounding eligibility for clinical trials.  8:36 •    Where do you see this going down the line?  10:05 •    Has your company looked into how to these services can impact diversifying clinical trial enrollment?  12:04 •    What are some challenges your company has faced?  13:50 •    How quickly do you think growth will accelerate in this space?  15:26 •    How will this work and resource have major impacts on drug development in a more accelerated way than in the past?  16:11 •    From the patient-facing side, have you faced any challenges concerning patients’ willingness to be enrolled in clinical trials?  18:22 •    What is next for you, and where do you see yourself in twenty years?  19:13 •    Do you have any concerns about AI in health care? […] What should we be aware of when utilizing AI in this space?  19:45 •    Jain and van Harten on the challenges and setbacks that come from outdated and inaccurate clinical trial databases.  21:35 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:50 •    How to contact van Harten 24:28 •    Thanks for listening 25:17 Michel van Harten, MD, is the CEO of myTomorrows.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Michel van Harten can be reached via email [email protected]. 

Disclosures: Jain and van Harten report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Melody Harris about the evolution of precision medicine, what physicians and companies can do to help patients better understand precision oncology and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Harris 0:20 •    The interview 1:11 •    Tell us about how you ended up in this niche role. 1:32 •    How did you make the decision to move from practicing law to transitioning your career into this space?  3:56 •    Jain and Harris on the “hype” around precision medicine. 7:11 •    What is the central thesis of the work at NeoGenomics? 10:36 •    What do you feel companies need to be doing to make expectations surrounding diagnoses more transparent for patients?  11:49 •    Where do you think this is all going in the future? Where do you think we’ll be in another ten or twenty years?  13:30 •    What do you see yourself doing next?  19:04 •    How can companies address the disparities in health care access, especially in underserved areas?  21:06 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:32 •    How to contact Harris 24:30 •    Thanks for listening 25:14 Melody Harris serves as chief operations officer and president of informatics at NeoGenomics, a leading oncology testing services company.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Harris can be reached at [email protected]. 

Disclosures: Jain and Harris report no relevant financial disclosures. 

In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting. With insights from Benjamin P. Levy, MD, and top headlines from the conference, Meeting Mic is your on-the-go source for highlights, pearls, and perspectives across all specialties.

Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:49

Read the full coverage here:

Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’

Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Perioperative nivolumab improves outcomes in resectable NSCLC

Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Despite progress, barriers to lung cancer biomarker testing persist

Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD.

Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Levy at the time of posting.

In this episode, host Shikha Jain, MD, speaks with Alice Chen, MD, about the impact of misinformation and disinformation during elections, the health care issues on the 2024 ballot and more. Content warning: This episode discusses sensitive topics surrounding women’s health and reproductive rights. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Chen 0:32 •    The interview 1:38 •    How did you get into the public health and advocacy spaces? 1:58 •    Have you seen an evolution in medical professionals becoming more involved in politics and advocacy?  5:08 •    How has misinformation impacted politics, health care, policy and the election? 7:25 •    As health care workers, how do we address misinformation to help our communities and patients? 10:51 •    Do you feel that health care workers should use social media for this type of advocacy work?  15:26 •    Is there more of a need for health care workers to be doing this work now than it was pre-social media?  18:14 •    Jain and Chen on how discussions around politics have changed in the last decade.  26:05 •    What are the major health care topics being discussed and impacted by this upcoming election? Why is health on the ballot?  28:33 •    Jain and Chen on women’s health and why it matters in this election.  30:58 •    What are health care workers doing to promote advocacy?  37:05 •    If you could summarize this episode in one minute, what would you want listeners to take away? 45:36 •    How to contact Chen 46:11 •    Thanks for listening 46:53 Alice T. Chen, MD, is a mom, physician and national leader in public health, physician advocacy and community organizing.  She serves as the co-chair of the board of directors of Health Care Without Harm.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Chen can be reached @atychen on X and on LinkedIn. 

Disclosures: Jain and Chen report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Amita Patnaik, MD, FRCPC, about providing patient access to breakthrough drug developments, bringing early phase cancer trials to physicians and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Patnaik 0:21 •    The interview 1:23 •    How did you decide to become an oncologist, and how did you end up co-founding the START Center for Cancer Research?  1:32 •    Can you tell me about START’s overarching purpose and where you see its need being most fulfilled? […] What do you hope START will accomplish in the next five to ten years?  11:33 •    How successful has START been at including underrepresented patient populations in clinical data? 17:52 •    What are some challenges you’ve found as you have navigated through founding a company and executing its mission? 21:48 •    What is next for you?  25:21 •    If someone else wanted to create a company like START, what are some tips you would give them?  27:23 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 32:03 •    How to contact Patnaik 34:44 •    Thanks for listening 35:27 Amita Patnaik, MD, FRCPC, is an internationally recognized medical oncologist and the co-founder of the START Center for Cancer Research.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Patnaik can be reached via email [email protected] or via the START website.

In this episode, host Shikha Jain, MD, speaks with Annmarie Ison about developing safe and accurate software, how software can improve health care disparities and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Ison 0:25 •    The interview 1:10 •    Tell me about how you got into this space […] Can you explain what software development is?  1:34 •    What is Elekta and what does the company do?  10:24 •    How do you feel that this type of innovation is transforming cancer care and treating oncology patients? 13:19 •    How is Elekta and its services helping to address health care disparities? 19:32 •    Where do you think AI fits into the bigger picture of the cancer care landscape?  24:53 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:29 •    How to contact Ison 30:25 •    Thanks for listening 31:05 Annmarie Ison is head of customer service for the software business line at Elekta. She has over 25 years of experience as a software development professional, specializing in product development and software architecture for information management systems and radiation therapy delivery devices.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Ison can be reached via email [email protected] or via LinkedIn.  Disclosures: Jain and Ison report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Brian Fiske about bringing biotech business ideas to fruition, antibody drug conjugate developments and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Fiske 0:21 •    The interview 1:45 •    How did you get to where you are today, and how did you become interested in this specific area of health care?  2:06 •    What is a timeline from start to finish to bringing an innovative idea to fruition?  6:01 •    How long does it take to form an actual company from an idea?  11:20 •    How do you figure out who you need on your team to move an idea forward? 15:11 •    Tell us about your previous positions at biotech companies, and how did they help lead you into your current space? 20:22 •    What excites you about your job? […] Why do you feel the drive and desire to do this type of work?  24:40 •    Where do you see the work at Mythic Therapeutics doing in the next five to ten years for patient care?  26:27 •    How can we work towards making sure this type of innovative work is available and accessible to patients?  29:20 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 31:16 •    How to contact Fiske 32:12 •    Thanks for listening 32:56 Brian Fiske is chief scientific officer and co-founder of Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate therapies for the treatment of a wide range of cancers.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Fiske can be reached via LinkedIn or the Mythic Therapeutics website.   Disclosures: Jain and Fiske report no relevant financial disclosures.